GlassScriptPhysician profile
Richard Pomerantz
NPI 1154321321
$1,894.05
in general payments reported to CMS, 2019-2025
26 companies · $272 in 2025
The $272 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.62 · 2020: $19.32 · 2021: $70.33 · 2022: $71.87 · 2023: $1,282 · 2024: $161 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,714.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $241.69 | 2023-2025 | Inspire |
| Glaxosmithkline, LLC. | $202.87 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $200.73 | 2023-2025 | Tezspire, Breztri, Fasenra |
| Actelion Pharmaceuticals US, INC. | $180.16 | 2023 | Opsumit, Uptravi |
| Regeneron Healthcare Solutions, INC. | $156.51 | 2023-2024 | Dupixent |
| Ani Pharmaceuticals, INC. | $129.91 | 2023 | Purified Cortrophin Gel |
| Grifols USA, LLC | $119.37 | 2021-2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $75.98 | 2021-2023 | Yupelri |
| Amgen INC. | $69.36 | 2023 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.75 | 2022-2024 | Ofev, Stiolto Respimat |
| Harmony Biosciences LLC | $60.16 | 2023-2024 | Wakix |
| Insmed, INC. | $58.93 | 2023-2025 | Arikayce |
| Genzyme Corporation | $44.87 | 2023 | |
| Jazz Pharmaceuticals INC. | $37.68 | 2025 | |
| Novartis Pharmaceuticals Corporation | $34.54 | 2022-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $28.72 | 2023 | |
| Verona Pharma, INC. | $22.22 | 2025 | Ohtuvayre |
| United Therapeutics Corporation | $21.35 | 2025 | Tyvaso |
| Inogen, INC. | $20.69 | 2023 | Inogen |
| Bayer Healthcare Pharmaceuticals INC. | $20.35 | 2023 | |
| Allergan, INC. | $19.32 | 2020 | |
| Baxter Healthcare | $19.29 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Electromed, INC. | $17.62 | 2019 | |
| Ethicon INC. | $15.37 | 2023 | Monarch Platform |
| Csl Behring | $14.64 | 2021 | |
| Pulmonx Corporation | $12.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Pomerantz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.